CHU Martinique, UF1441 Registre Des Cancers de La Martinique, Pôle de Cancérologie Hématologie Urologie, Fort de France, Martinique, France.
CHU Martinique, UF3596 Recherche en Cancérologie, Pôle de Cancérologie Hématologie Urologie, Fort de France, Martinique, France.
BMC Cancer. 2023 Aug 10;23(1):739. doi: 10.1186/s12885-023-11072-1.
Thyroid cancer (TC) overall survival at 5 years was estimated at 97% in mainland France over 2010-2015. Its prognosis is known to be affected by patient age, tumor histology, size, and extension. This study aims to describe overall survival of thyroid cancer patients diagnosed between 2008 and 2018 in Martinique.
We included in this retrospective analytical study all patients who were diagnosed with thyroid cancer. An overall survival analysis at 1, 3 and 5 years of thyroid cancer patients diagnosed in Martinique from 2008 to 2018 was conducted. Prognostic factors associated with survival have been identified. Stage at diagnosis and patterns of care among thyroid cancer patients were analyzed.
A total of 323 thyroid cancer patients were registered between 2008 and 2018. Papillary carcinomas represented 83% of diagnoses. Local stage or locally advanced invasion was found in 264 (88%) patients. 221 Multidisciplinary Teams reports files were reviewed. The overall survival observed in this population is 97% [93-99] at 1 year, 93% [88-97] at 3 years and 91% [85-95] at 5 years. Anaplastic, poorly differentiated and medullar tumors had lower survival rates at 5 years (39% [13-65]) compared to papillary tumors (93% [89-96]). We found that metastatic stage at diagnosis (HR = 3.1[1.3-7.6]; p = 0.01) and tumor size > 3 cm (HR = 2.7 [1.1-6.3]) were independent prognostic factors for OS in our population.
The survival rates of thyroid cancer in Martinique are comparable to those observed in France.
2010-2015 年，法国本土甲状腺癌（TC）的 5 年总生存率估计为 97%。其预后已知受患者年龄、肿瘤组织学、大小和扩散程度的影响。本研究旨在描述 2008 年至 2018 年期间在马提尼克岛诊断出的甲状腺癌患者的总生存率。
我们将所有在马提尼克岛诊断出患有甲状腺癌的患者纳入这项回顾性分析研究中。对 2008 年至 2018 年期间在马提尼克岛诊断出的甲状腺癌患者进行了 1 年、3 年和 5 年的总生存率分析。确定了与生存相关的预后因素。分析了诊断时的分期和甲状腺癌患者的治疗模式。
2008 年至 2018 年期间共登记了 323 例甲状腺癌患者。乳头状癌占 83%的诊断。264 例（88%）患者存在局部或局部晚期侵袭。共审查了 221 份多学科团队报告文件。该人群的总生存率为 1 年时 97%[93-99]，3 年时 93%[88-97]，5 年时 91%[85-95]。与乳头状瘤（93%[89-96]）相比，间变性、低分化和髓样肿瘤的 5 年生存率较低（39%[13-65]）。我们发现，诊断时的转移分期（HR=3.1[1.3-7.6]；p=0.01）和肿瘤大小>3cm（HR=2.7[1.1-6.3]）是我们人群中 OS 的独立预后因素。
马提尼克岛甲状腺癌的生存率与法国观察到的生存率相当。
